Idea Development Award – HT9425-23-PCARP-IDA
- up to USD500,000 over 3 years (Established Single PI Option) or USD$650,000 over 3 years (Early-career Investigator partnering PI Option)
- Pre-proposals due 10 July 2023
- Single PI Option – investigators at or above Associate Professor level
- Early-Career Partnering Option – initiating PI (mentor) Assistant Professor or above; Early-career investigator less than 10 years post PhD
- Supports development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer.
- supports innovative ideas with the potential to yield impactful data and new avenues of investigation
- clinical trials or proof-of-concept intervention studies on human subjects not allowed
- must address at least one focus area
Translational research Partnership Award – HT9425-23-PCARP-TRPA
- up to USD$750,000 over 3 years
- Pre-proposals due 10 July 2023
- Supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in pancreatic cancer in a manner that would be less readily achievable through separate efforts.
- Two Principal Investigators are required, at level of Assistant Professor or above. One partner in the collaboration must function as a research scientist and the other as a clinician investigator (Initiating PI and Partnering PI)
- Clinician investigators must be an MD, MD/PhD, or equivalent with clinical duties.
- Postdoctoral and clinical fellows are not eligible.
- At least one member of the partnership must have expertise either in pancreatic cancer research or pancreatic cancer patient care.
- Projects involving convergence science partnerships are strongly encouraged.
- Preliminary data required but does not necessarily have to be derived from pancreatic cancer studies
- must address at least one focus area
2023 Focus Areas
- Early detection research for pancreatic cancer, including the prevalence in individuals with pre-diabetes and diabetes and/or those in underserved ethnic and minority communities
- Supportive care interventions, patient-reported outcomes, quality of life, and perspectives during diagnosis, treatment, and survivorship
- Barriers to the implementation of health care, including ways to overcome socioeconomic, geographic, or ethnic and racial disparities
- Identification and characterization of pancreatic cancer risk including genetic and environmental risk factors, such as diet, obesity, and microbiome
- Understanding the relationship between metabolic disruptions in pancreatic cancer and their systemic effects, including diabetes and cachexia
- Understanding tumor development and progression, from precursors to metastasis
- Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response
- Biomarkers to predict therapeutic response and guide management strategies
- New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance
Supporting documents for download
Reference table of award mechanisms – 23pcarpreftable
Idea Development Award – HT9425-23-PCARP-IDA-GG
Translational Research Partnership Award – HT9425-23-PCARP-TRPA-GG
